Elucid Commences International PRE-VUE CT Registry Study

July 18, 2024—Elucid announced the initiation of site recruitment for the international, multicenter, retrospective PRE-VUE CT Registry study at SCCT2024, the Society of Cardiovascular Computed Tomography annual scientific meeting held July 18-21 in Washington, DC.

According to the company, PRE-VUE is evaluating the prognostic accuracy of PlaqueIQ Elucid’s next-generation, histology-defined plaque analysis, as well as its investigational plaque-based FFR_CT (fractional flow reserve derived from CT) software in predicting major cardiac adverse events in patients who have received clinically indicated coronary CT angiography (CCTA).

The study will include at least 30 centers and a pool of at least 10,000 patients aged ≥18 years, all of whom underwent CCTA with continuous follow-up for a minimum of 36 months.

The lead investigators for PRE-VUE are Carlo De Cecco, MD, with Emory University in Atlanta, Georgia, and Márton Kolossváry, MD, with Gottsegen National Cardiovascular Center in Budapest, Hungary.

“This registry will aim to provide worldwide physicians the most accurate information on coronary plaque to improve cardiovascular risk prediction and support the selection of patient-specific treatment,” commented Dr. De Cecco in the company’s press release. “The ultimate goal is to positively impact cardiovascular health globally with a reduction in cardiovascular events.”

Dr. Kolossváry added, “The PRE-VUE registry will empower us to see the true additive value of CT-derived, histologically validated plaque volumes in predicting future adverse cardiovascular events.”

The company stated that it seeks to address the need for new objective and noninvasive diagnostic methods that more accurately quantify and characterize plaque, including vulnerable plaque, based on actual histology.

Euclid’s PlaqueIQ is a histology-validated, FDA-cleared software that noninvasively quantifies and characterizes noncalcified plaque and its components, such as lipid-rich necrotic core, giving potential insights into high-risk plaque. The company is also pursuing an indication for noninvasive measurement of FFR_CT derived from its plaque algorithm to measure coronary blockages and the extent of ischemia, noted the press release.